Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.
CPI Card Group M&A Deal with Tricor Pacific Capital Partners
CPI Card Group Inc. announced the closing of a secondary public offering of 2,687,921 shares of common stock by selling stockholders Tricor Pacific Capital Partners. The offering included the full exercise of the underwriters' option to purchase additional shares, and the company received zero proceeds from the sale as it was entirely a resale of shares by existing holders.
Yarrow Bioscience entered into an underwriting agreement to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters fully exercised their option to purchase an additional 865,384 shares, bringing the total expected net proceeds to approximately $161.8 million after expenses.
Value
$172M
Counterparty
Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
Moleculin Biotech announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the AACR Conference on Pancreatic Cancer. The presentations will cover the drug's organotropism, its mechanism for targeting topoisomerase II, and its ability to stimulate CD8+ T cell cytotoxicity in pancreatic tumors. These findings support the company's broader development of Annamycin beyond its lead indication in acute myeloid leukemia (AML).
Curaleaf Holdings has filed an application with the Alberta Securities Commission to halt Aurora's at-the-market (ATM) share issuance program during Curaleaf's pending acquisition offer. Curaleaf argues that Aurora's continued share sales at prices below the $4.00 offer price are an abusive defensive tactic that has increased the deal's cost by over $11 million and diluted shareholders by approximately 11%.
Trilogy Metals closed a $17.8 million strategic equity investment from the U.S. Department of War, issuing 8,215,570 units at $2.17 per unit. The U.S. Government becomes an approximately 10% shareholder to advance domestic copper and cobalt supply from the Upper Kobuk Mineral Projects in Alaska.
Allarity Therapeutics announced that its newly formed SPAC, Allarity Acquisition Corp., has filed a Registration Statement for a proposed $100 million IPO ($115 million including overallotment). Allarity's subsidiary will act as the sponsor and is expected to own approximately 25% of the SPAC following the offering.
Crane Signs $240M M&A Deal with Trillium Flow Technologies
Crane Company has entered into a definitive agreement to acquire the U.S. pump business from First Reserve-backed Trillium Flow Technologies for approximately $240 million. The acquisition includes mission-critical brands such as Floway and Wemco, expanding Crane's Process Flow Technologies segment and its exposure to the municipal water and wastewater markets. The transaction is expected to close in the fourth quarter of 2026, adding a business with approximately $115 million in expected annual revenue.
Ondas Signs $205M M&A Deal with Gate Technologies Ltd. and Bron Technologies sp. z.o.o
Ondas Inc. completed the acquisition of 100% of the share capital of Israel-based Gate Technologies Ltd. and its European affiliate Bron Technologies for $105 million in cash and approximately 10.7 million shares of common stock. The deal includes up to $185 million in contingent earn-out payments and expands Ondas' precision-strike platform with advanced electronic safe-and-arm and fuzing technology.
Value
$205M
Counterparty
Gate Technologies Ltd. and Bron Technologies sp. z.o.o
Onconetix provided a $5.0 million strategic bridge financing facility to Realbotix, LLC, the target of its previously announced pending acquisition. The facility is non-interest bearing and will be automatically cancelled and discharged upon the closing of the all-stock merger. This update supports the working capital needs of Realbotix as the parties work toward completing the transaction.
Harvard Apparatus Regenerative Technology Capital Raise of $2.84M
Harvard Apparatus Regenerative Technology closed a private placement of 2,703,727 shares of common stock at $1.05 per share for total proceeds of approximately $2.84 million. The transaction included a $717,911 debt-for-equity conversion by CEO Jerry (Junli) He, who cancelled outstanding bridge promissory notes in exchange for shares at the same offering price.
Biofrontera received FDA approval for its supplemental New Drug Application (sNDA) for Ameluz in combination with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma. This marks the first and only photodynamic therapy approved in the U.S. for a skin cancer, significantly expanding the addressable market for the company's PDT platform.
“FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor.”
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
Baldwin Insurance Group Signs $7.7B M&A Deal with Sequence Holdings and DFO Management
The Baldwin Insurance Group, Inc. has entered into a definitive agreement to be acquired and taken private by Sequence Holdings and DFO Management (the Dell Family Office) for $32.50 per share in cash. The transaction is valued at approximately $7.7 billion, including $3.1 billion of net debt, and represents an 88% premium to the company's unaffected closing price. Upon closing, expected in Q1 2027, Baldwin will become a privately held company with eligible employees retaining a minority equity stake.
XBP Global Holdings entered into securities purchase agreements to raise approximately $6.05 million through a private placement of 2,275,245 shares of common stock. The offering included participation from company insiders, including the CEO, CFO, and affiliates of the Executive Chairman and a Board member, at prices ranging from $2.55 to $2.83 per share. Proceeds are intended for general corporate purposes, and the company has committed to filing a resale registration statement for the shares by September 22, 2026.
Value
$6.05M
Counterparty
Avenue Capital Group, HCI LLC, and other accredited investors
Celularity Inc. has regained compliance with Nasdaq's minimum bid price and minimum market value of listed securities requirements. However, the company remains deficient regarding the timely filing of its periodic reports and is working to complete those filings to fully regain compliance.
SmartKem, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 per share for 13 consecutive business days. The company had previously received a deficiency notice on March 5, 2026, and Nasdaq has now deemed the matter closed.
Future Vision II Acquisition M&A Deal with MicroTouch Technology Inc.
Future Vision II Acquisition Corp. issued a $65,000 promissory note to its sponsor, Hwei Super Speed Co., Ltd., to fund a one-month extension of its business combination deadline to October 13, 2026. The company confirmed it is continuing to pursue its previously announced merger with MicroTouch Technology Inc. and clarified that redemption funds from a prior extension event were paid at $11.03 per share.
Summit Therapeutics' partner Akeso presented updated Phase III HARMONi-2 trial data showing ivonescimab monotherapy significantly improved overall survival compared to pembrolizumab in PD-L1-positive advanced NSCLC. Ivonescimab reduced the risk of death by 27% (HR 0.73) and improved median overall survival by 8.2 months (30.8 months vs 22.6 months).
Bowman Consulting Group Signs $1B M&A Deal with Bernhard Capital Partners
Bowman Consulting Group announced the expiration of the 35-day 'go-shop' period under its previously announced merger agreement with Bernhard Capital Partners. No alternative acquisition proposals were received during the solicitation period, and the company is now subject to 'no-shop' provisions. The all-cash transaction, valued at approximately $1.0 billion or $43.00 per share, is expected to close in the fourth quarter of 2026.
Cambium Networks' subsidiary, Cambium Networks, Ltd, has entered administration in the UK, with administrators appointed to sell assets or wind up the business. In connection with this insolvency, the company reduced its global workforce by 260 employees (53.6%) and terminated the role of Senior VP of Products, Vibhu Vivek.
Enbridge Inc. completed a bought deal public offering of 44,735,000 common shares, including the full exercise of an over-allotment option. The offering generated gross proceeds of approximately CDN$3.0 billion. The transaction was conducted through a syndicate of underwriters led by RBC Dominion Securities and CIBC World Markets.
Counterparty
RBC Dominion Securities Inc. and CIBC World Market Inc.
Nomadar Signs $2M M&A Deal with Fox Soccer Academy
Nomadar Corp. has entered into a definitive equity purchase agreement to acquire a majority interest in Fox Soccer Academy (FSA), which operates youth soccer programs in New York, North Carolina, the UK, and Austria. The consideration includes a $2 million base cash payment and the issuance of Class B Units in a subsidiary representing a 49% retained interest by the sellers. The deal expands Nomadar's international sports development platform by integrating FSA's Premier League-inspired curriculum with Nomadar's existing Spanish football initiatives.
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The study met its primary endpoint with a statistically significant reduction in HAM-A scores compared to placebo (p<0.0001) and was generally well tolerated. The company plans to file an NDA in the first half of 2027 following a pre-NDA meeting with the FDA in Q4 2026.
Thryv Holdings Divestiture to Coldwater YP, LLC for $142M
Thryv Holdings, Inc. has entered into a definitive agreement to sell its print directories business in the U.S., Australia, and New Zealand to Coldwater YP, LLC for $142 million in cash. The company intends to use the proceeds to reduce debt and focus resources on its AI-powered SaaS Growth Platform. The transaction is expected to close in the fourth quarter of 2026.
Value
$142M
Counterparty
Coldwater YP, LLC (an affiliate of Carolwood, L.P.)
Cabaletta Bio announced the completion of warrant exercises from its June 2025 public offering, resulting in total aggregate gross proceeds of approximately $128.2 million. The warrants, which had an exercise price of $2.50 per share, expired on September 12, 2026, with the vast majority of exercises occurring between July 1, 2026, and the expiration date.
Perdoceo Education Signs $224M M&A Deal with South University Savannah, LLC
Perdoceo Education Corporation entered into a definitive agreement to acquire 100% of South University for an initial cash payment of $150 million, plus $18 million in deferred consideration and up to $56 million in performance-based earn-outs. South University is a leading health sciences-focused institution with 11 campus locations and approximately 10,500 students, generating $291 million in 2025 revenue. The transaction is expected to close as early as April 2027 and will expand Perdoceo's graduate health sciences and academic program offerings.
Telomir Pharmaceuticals announced positive preclinical in-vitro research findings demonstrating that its compound Telomir-Zn inhibited cell growth in both human and canine osteosarcoma models. The study, conducted with The Ohio State University, showed consistent anti-tumor activity at low drug concentrations, supporting a potential parallel development pathway for veterinary and human oncology indications.
Counterparty
The Ohio State University College of Veterinary Medicine
Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.
Earnings call
Sep 14, 2026, 8:00 AM ET
“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”
David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
AirJoule Technologies Signs $27M M&A Deal with Bitsink LLC
AirJoule Technologies acquired 100% of Bitsink LLC, a manufacturer of cooling and power infrastructure for AI and high-density data centers, for $18 million in cash and $9 million in common stock. The deal includes up to $40 million in additional performance-based earnout payments through 2029, significantly expanding AirJoule's footprint in the AI and HPC infrastructure market.
Texas Capital Bancshares Nasdaq/NYSE Compliance Notice
Texas Capital Bancshares is voluntarily withdrawing its common and preferred stock listings from Nasdaq to transfer them to the newly formed Texas Stock Exchange (TXSE). Trading is expected to begin on the TXSE on October 8, 2026, with a subsequent ticker symbol change from TCBI to TXCP scheduled for November 9, 2026.